Drug patent evergreening works, until it doesnt
Ekta Gupta, chief of gastroenterology at the University of Maryland Medical Center, explains that GLP-1 medications (also known as GLP-1 agonists) mimic hormones that help regulate blood sugar and appetite
16,17,18,19 As new indications continue to be developed, GLP-1 drugs demonstrate immense potential in the medical field, with future research expected to expand their therapeutic applications
This is why some women find that they need slightly higher doses during certain phases of their cycle or during perimenopause to maintain the same level of appetite control
Gastrointestinal effects represent the most frequently reported adverse reactions, occurring in a substantial proportion of patients, particularly during treatment initiation and dose escalation: Nausea (very common, affecting more than 1 in 10 people) typically peaks during the first few weeks and often diminishes with continued treatment [1] [2] Diarrhoea (very common, affecting more than 1 in 10 people) Vomiting (common, affecting up to 1 in 10 people) Abdominal pain, constipation, and dyspepsia occur with variable frequency Reduced appetite is an expected pharmacological effect contributing to weight loss but may occasionally be excessive These gastrointestinal symptoms usually improve over time as the body adjusts to the medication
